Update on the Management of Bipolar Illness [CME]
J Clin Psychiatry 1998;59:484-495
© Copyright 2014 Physicians Postgraduate Press, Inc.
Purchase This PDF for $40.00
If you are not a paid subscriber, you may purchase the PDF.
(You'll need the free Adobe Acrobat Reader.)
Receive immediate full-text access to JCP. You can subscribe to JCP online-only ($86) or print + online ($156 individual).
With your subscription, receive a free PDF collection of the NCDEU Festschrift articles. Hurry! This offer ends December 31, 2011.
If you are a paid subscriber to JCP and do not yet have a username and password, activate your subscription now.
As a paid subscriber who has activated your subscription, you have access to the HTML and PDF versions of this item.
Click here to login.
Did you forget your password?
Still can't log in? Contact the Circulation Department at 1-800-489-1001 x4 or send email
In his opening remarks, Richard C. Shelton, M.D., chairman of the conference, remarked
that he and his colleagues were recently lamenting the difficulty in recruiting subjects
for clinical trials of unipolar and bipolar disorders. One of the factors influencing the
current lack of patients for research studies is that there are fewer untreated or
inadequately-treated individuals with these disorders because of the relative success of
pharmacotherapeutic interventions. On the other hand, he offered, clinicians now see a
larger proportion of treatment-refractory unipolar and bipolar patients; consequently,
clinicians are shifting their thinking toward more complex treatment approaches.
As an educator, Dr. Shelton noted, he is somewhat concerned that the older effective
treatment modalities—such as lithium, tricyclic antidepressants, and monoamine
oxidase inhibitors—are being overlooked in favor of newer pharmacologic agents. Many
psychiatric residents complete their training without ever having used lithium, he said,
and one of the focuses of this conference is the examination of the current position of
lithium as a pharmacologic intervention in the treatment of bipolar illness.